Overview

A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

To demonstrate the superiority of YM060 to a placebo in global assessment of relief of overall IBS symptoms and stool form normalization, and to evaluate safety in female patients with diarrhea-predominant irritable bowel syndrome (D-IBS).

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Ramosetron